CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
Jean Sébastien Hulot, Jean Philippe Collet, Guillaume Cayla, Johanne Silvain, Frédérick Allanic, Anne Bellemain-Appaix, Stuart A. Scott, Gilles Montalescot
Research output: Contribution to journal › Article › peer-review
108Scopus
citations
Fingerprint
Dive into the research topics of 'CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients'. Together they form a unique fingerprint.